Real‐Time Continuous Glucose Monitoring Use and Kidney Function Among People With Diabetes and CKD or At‐Risk for CKD

Introduction Continuous glucose monitoring (CGM) use may benefit people with diabetes and chronic kidney disease (CKD). In this propensity‐matched, retrospective analysis using Truveta‐provided de‐identified EMR data, changes in kidney function and glycemia were compared between cohorts starting real‐time CGM (RT‐CGM) use and CGM non‐users (No CGM). Methods Adults with type 1 or type 2 diabetes, treated with any insulin, with estimated glomerular filtration rate (eGFR) of 15–89 mL/min/1.73 m 2 were included. Changes in eGFR, albumin‐to‐creatinine ratio (ACR), and HbA1c between baseline and 3‐year follow‐up were assessed. Results RT‐CGM initiation ( N = 518 per cohort) was associated with a significantly slower decline in eGFR compared to No CGM. There was no significant difference in change in ACR between the groups ( N = 138 per cohort). RT‐CGM use ( N = 461 per cohort) was associated with a significantly greater decrease in HbA1c compared to No CGM. Conclusions These findings support RT‐CGM initiation among people with diabetes and CKD or at risk for CKD.